The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.